# Preferred Drug List

# NEW DRUG REVIEW

**Proprietary Name:** Ampyra™

**Common Name:** Dalfampridine

**PDL Category: Multiple Sclerosis Agents**

| Comparable Products | Preferred Drug List Status |
|---|---|
| N/A | |

## Summary

**Indications and Usage:** Indicated to improve walking in patients with multiple sclerosis (MS), as demonstrated by an increase in walking speed.[1]

**Mechanism of Action:** Potassium channel blocker thought to increase conduction of action potentials in demyelinated axons through inhibition of potassium channels. [1]

**Dosage Forms:** Tablets: 10mg

**Recommended Dosage:** 10mg twice daily, with or without food.[1]

**Common Adverse Drug Reactions:** Urinary tract infection, insomnia, dizziness, headache, nausea, weakness, back pain, balance disorder, swelling in the nose or throat, constipation, diarrhea, indigestion, throat pain, and burning, tingling, or itching of the skin. [1]

**Contraindications:** History of seizure. Moderate or severe renal impairment.[1]

**Manufacturer:** Acorda Therapeutics, Inc.

**Analysis:** Ampyra™ is the first drug indicated to improve walking speed in patients with MS. In the trials used to gain FDA approval, Ampyra™ was compared to placebo. In clinical trials, patients treated with Ampyra™ experienced faster walking speeds as measured by the Timed 25 Foot Walk (T25FW) as compared to placebo (Trial 1 34.8% vs 8.3%; Trial 2 42.9% vs 9.3%). Ampyra™ can cause seizures when given at doses higher than recommended (10mg twice daily). Ampyra™ should be avoided in patients with a history of seizure and in patients with moderate to severe kidney disease. It is recommended that Ampyra™ be added to the Preferred Drug List as a non-preferred drug and recommend the Drug Utilization Review (DUR) Commission develop criteria.

**IME Recommendation:**

- ☐ Preferred Drug
- ☐ Recommended Drug
- ☒ Non-Preferred Drug
- ☐ Non-Recommended Drug
- ☐ Non-Preferred Drug with Conditions

1. Ampyra™ [package insert]. Hawthorne, NY: Acorda Therapeutics, Inc.; 2010.

Deleted: 7/28/2010

Prepared By: Iowa Medicaid Enterprise Date: 7/30/2010